EACS 2023

EACS 2023
October 18-21, 2023
Warsaw, Poland

European AIDS Conference.

Explore more information for Gilead HIV / AIDS therapies
Results (8)

Association of Susceptibility to Broadly Neutralizing Antibodies and Presence of Capsid CTL Epitopes During Acute HIV-1 Infection

Resistance Analysis of Long-Acting Lenacapavir in Heavily Treatment‑Experienced People with HIV after 104 Weeks of Treatment

Assessing Phenotypic Effect of Integrase Strand Transfer Inhibitor (INSTI)-Based Resistance Substitutions Linked to Failures on Cabotegravir

Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-experienced (TE) people with HIV (PWH) with baseline symptoms of depression, anxiety or insomnia (DAI) in the observational BICSTaR study

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in antiretroviral treatmentnaïve (TN) and -experienced (TE) people with HIV (PWH): 3-year effectiveness and safety outcomes in the BICSTaR observational cohort

Insights and experiences from the CAPELLA trial: perspectives of healthcare professionals and study coordinators on Lenacapavir use amongst heavily treatment-experienced people with HIV

Follow-up of injection site reactions in clinical studies of people using lenacapavir every 6 months for HIV treatment

Restarting bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) after virologic rebound: a pooled analysis of studies in people with HIV-1